 "sun pharma")
Shares of Sun Pharmaceutical Industries (Sun Pharma) gained ground for the fifth straight day, up 4 per cent to Rs 425 on the BSE on Monday in intra-day deals after Morgan Stanley 'double upgraded' the stock on a possible uptick in earnings going ahead. The foreign brokerage firm has maintained a target price of Rs 505 per share, 19 per cent higher from the current levels.
In the past one week, Sun Pharma has outperformed the market by surging 16 per cent, as compared to 0.20 per cent decline in the S&P BSE Sensex.
“We are double upgrading
In the past one week, Sun Pharma has outperformed the market by surging 16 per cent, as compared to 0.20 per cent decline in the S&P BSE Sensex.
“We are double upgrading
